一个儿科病例的B细胞前体ALL与Blinatumomab相关的脑病变
Maiko Shimomura1, Mari Tanaka, Yoshiyuki Kobayashi
1Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.
Journal of pediatric hematology/oncology
|July 15, 2024
概括
布利纳图莫马布可以导致罕见但严重的神经事件,如脑病变在患有B细胞前体急性淋巴细胞白血病 (BCP-ALL) 的儿童. 这一案例凸显了发作,脑梗塞和长期神经损伤的风险.
科学领域:
- 儿科瘤学 儿科瘤学
- 神经瘤学神经瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 布利纳图莫马布是一种CD3/CD19导向的双特异性T细胞参与剂,是复发性或耐火性B细胞前体急性淋巴细胞白血病 (BCP-ALL) 的关键治疗方法.
- 虽然有效,但blinatumomab与严重的不良事件有关,包括细胞因子释放综合征和神经毒性.
- 神经事件,特别是脑病变,是罕见的并发症,关于其表现和管理的现有文献有限.
更多相关视频
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
2.4K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)